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Sporadic miscarriage is the most common complication of early pregnancy. Two or three consecutive pregnancy
losses is a less common phenomenon, and this is considered a distinct disease entity. Sporadic miscarriages are
considered to primarily represent failure of abnormal embryos to progress to viability. Recurrent miscarriage is
thought to have multiple etiologies, including parental chromosomal anomalies, maternal thrombophilic disorders,
immune dysfunction and various endocrine disturbances. However, none of these conditions is specific to recurrent
miscarriage or always associated with repeated early pregnancy loss. In recent years, new theories about the
mechanisms behind sporadic and recurrent miscarriage have emerged. Epidemiological and genetic studies
suggest a multifactorial background where immunological dysregulation in pregnancy may play a role, as well as
lifestyle factors and changes in sperm DNA integrity. Recent experimental evidence has led to the concept that the
decidualized endometrium acts as biosensor of embryo quality, which if disrupted, may lead to implantation of
embryos destined to miscarry. These new insights into the mechanisms behind miscarriage offer the prospect of
novel effective interventions that may prevent this distressing condition.
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Sperm DNA IntegrityIntroduction
The term ‘miscarriage’ is applied to many complications
of early pregnancy, and it is important to be clear on
terminology. In 2005, the European Society of Human
Reproduction and Embryology (ESHRE) introduced a
revised terminology regarding early pregnancy events
[1]. A pregnancy loss that occurs after a positive urinary
human chorionic gonadotropin (hCG) or a raised serum
β-hCG but before ultrasound or histological verification is
defined as a ‘biochemical loss’. In general, these occur
before 6 weeks of gestation. The term clinical miscarriage
is used when ultrasound examination or histological
evidence has confirmed that an intrauterine pregnancy
has existed. Clinical miscarriages may be subdivided
into early clinical pregnancy losses (before gestational
week 12) and late clinical pregnancy losses (gestational
weeks 12 to 21). There is no consensus on the number of
pregnancy losses needed to fulfill the criteria for recurrent
miscarriage (RM), but ESHRE guidelines define RM as* Correspondence: n.s.macklon@southampton.ac.uk
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reproduction in any medium, provided the orthree or more consecutive pregnancy losses before 22
weeks of gestation [2]. Although the above-mentioned
terminology is widely used, it is also acknowledged that it
is not always clinically useful. Indeed, a recent paper has
proposed classification according to developmental periods
in gestation [3].
Clinical miscarriage is both a common and distressing
complication of early pregnancy. In recent years, progress
in the fields of cytogenetics and immunogenetics and a
greater understanding of implantation and maternal-
embryo interactions has offered new insights into the
possible causes of this condition, and opened up new
avenues for research into its prevention and treatment. In
this article we review the key mechanisms thought to
underlie miscarriage, and discuss emerging concepts in
this field (Table 1).Epidemiology of sporadic and recurrent miscarriage
Human reproduction is characterized by its inefficiency.
Prospective cohort studies using sensitive and specific daily
urinary hCG assays in women trying to conceive have
demonstrated that only around one-third of conceptions
progress to a live birth [34-36]. An estimated 30% of
human conceptions are lost prior to implantation and aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Overview of miscarriage-associated factors and their possible causal role for miscarriage/recurrent miscarriage,
possible treatments and proposals for future research




Possible treatment and its
documented effect
Future research
Parental chromosome abnormalities [4,5] Strong PGD: weak Identification of high risk carriers
through clinical history; RCT of
PGD/no PGD
Autoantibodies [6,7] Moderate Prednisone, IvIg: weak RCTs of prednisone and/or IvIg
NK cell dysfunction [8-10] Weak to moderate Prednisone, IvIg: weak Develop standardized methods of
measuring NK cells in the endometrium;
establish normal values of NK cells in
the blood and endometrium during
pregnancy
Abnormal HLA-G expression [11] Weak to moderate Prednisone, IvIg: weak Develop standardized methods for
measuring soluble and membrane-
bound HLA-G
Hereditary thrombophilia [12,13] Moderate Heparin, LDA: weak RCTs of heparin and LDA
Acquired thrombophilia [12,14] Strong Heparin, LDA: moderate Larger RCTs of heparin and LDA
Thyroid autoimmunity [15-17] Strong Levothyroxine: weak RCTs of levothyroxin
PCOS [18] Weak Weight loss Cohort studies of miscarriage rates
subsequent to weight loss vs no
weight loss
Sperm DNA fragmentation [19,20] Moderate Sperm separation: no Identify the most specific assays;
establish methods for efficient sperm
selection.
Disrupted endometrial selection [21-26] Recently proposed
mechanism




Intervention studies using hormonal
treatments in the early luteal phase
are being carried out
Uterine malformations [27,28] Weak to moderate Septal resection RCTs of septal resection/no resection
hCG gene polymorphisms [29,30] Weak to moderate hCG supplementation: weak RCTs of hCG supplementation
Alcohol consumption [31] Moderate Alcohol cessation NA
Obesity [32,33] Weak to moderate Weight loss: weak Cohort studies of miscarriage rates
subsequent to weight loss vs no
weight loss
hCG human chorionic gonadotropin, HLA human leukocyte antigen, IvIg intravenous immunoglobulin, LDA low-dose aspirin, NK natural killer, PCOS polycystic
ovary syndrome, PGD preimplantation genetic diagnosis, RCT randomized controlled trial.
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menstrual period, that is in the third or fourth week of
gestation. These are often termed preclinical losses [37]
(Figure 1). Finally, the incidence of early clinical pregnancy
loss is estimated to be 15% of conceptions with a signifi-
cant variation according to age. Thus, the incidence ranges
from 10% in women aged 20 to 24 years to 51% in women
aged 40 to 44 years [38]. Late losses between 12 and 22
weeks occur less frequently and constitute around 4% of
pregnancy outcomes [39].
Compared to sporadic miscarriage the prevalence of
RM is considerably lower irrespective of whether bio-
chemical losses are included or not. If only clinical
miscarriages are included the prevalence is 0.8% to
1.4% [40]. If, however, biochemical losses are included
the prevalence is estimated to be as high as 2% to 3%.
Since the incidence of RM is greater than would be
predicted by chance, it is considered to represent adisease entity defined by a series of events, with a number
of possible etiologies [41].
Mechanisms and reasons for ‘physiological’ early
pregnancy loss
It is a generally accepted assumption that sporadic preg-
nancy losses occurring before an embryo has developed
represent a ‘physiological’ phenomenon, which prevents
conceptions affected by serious structural malformations
or chromosomal aberrations incompatible with life from
progressing to viability. This concept is supported by
clinical studies in which embryoscopy was used to assess
fetal morphology prior to removal by uterine evacuation.
Fetal malformations were observed in 85% of cases
presenting with early clinical miscarriage [42]. The same
study also demonstrated that 75% of the fetuses had an
abnormal karyotype. Fetal chromosomal aneuploidies












Figure 1 The pregnancy loss iceberg: an overview of the outcome of spontaneous human conceptions. It is estimated that 70% of
conceptions are lost prior to live birth. The majority of these losses occur prior to implantation or before the missed menstrual period, and since
they are not revealed to the woman they are termed preclinical. In the pregnancy loss ‘iceberg’, they are therefore below the ‘waterline’. Figure
reproduced with permission from Oxford University Press [37].
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tive genomic hybridization to study the chromosomal
complement of all blastomeres in preimplantation human
embryos, more than 90% were found to have at least one
chromosomal abnormality in one or more cells [43]. The
clinical implications of minor, mosaic and possibly ‘transient’
aneuploidies remain unclear. However, while most fetuses
with severe developmental defects will die in utero [44]
some aneuploidies can be compatible with survival to
term. The most commonly encountered is trisomy 21,
although 80% of affected embryos perish in utero or in the
neonatal period [45]. In most cases, the extra chromosome
is of maternal origin and caused by a malsegregation event
in the first meiotic division. The risk of this increases
with maternal age and may be considered to be a biological
rather than pathological phenomenon.
Although fetal chromosomal aberrations may be
identified in 29% to 60% of cases in women with RM,
the incidence decreases as the number of miscarriages
increases suggesting other mechanisms as a cause of the
miscarriage in RM couples with multiple losses [46].
In the near future diagnostic tests on fetal genetic
material isolated from maternal plasma will be a routine
procedure and probably substitute chorion villus sampling
and amniocentesis for prenatal diagnosis of fetal genetic
diseases [47]. Today, cell-free fetal DNA can be isolated
from the maternal circulation from 7 weeks of gestation,
and numerous studies have already been published where
next generation sequencing techniques have been applied
to detect fetal aneuploidies in cell-free fetal DNA [48-50].
Since it will soon be possible to sequence the entire fetal
genome from free fetal DNA in the maternal circulation,
new insights will be achieved in relation to bothchromosomal abnormalities and single gene disorders as a
cause of sporadic and recurrent miscarriage.
Karyotypic disorders
A chromosomal abnormality in one partner is found in
3% to 6% of RM couples, which is ten times higher than
the background population [51]. The most commonly
encountered abnormalities include balanced transloca-
tions and inversions that do not have any consequences
for the phenotype of the carrier, but in pregnancy there
is a 50% risk of a fetus with an unbalanced chromosomal
abnormality that can result in a miscarriage. This risk is
influenced by the size and the genetic content of the
rearranged chromosomal segments. Whether or not to
screen couples with RM for chromosomal abnormalities
remains a topic of debate. The argument for performing
this costly analysis is to optimize the counseling of RM
couples with respect to any subsequent pregnancy and
to avoid the birth of a child with congenital defects and
mental handicaps due to an unbalanced karyotype by
offering appropriate prenatal diagnostic screening.
The case against offering routine karyotyping for
couples with RM rests primarily on the findings of a large
index-control study with a mean follow-up period of 5.8
years. This study showed that carrier couples with at least
two previous miscarriages had the same chance of having
a healthy child as non-carrier couples with at least two
miscarriages (83% and 84%, respectively), and more
importantly a low risk (0.8%) of pregnancies with an
unbalanced karyotype surviving into the second trimester
[52]. Current clinical guidelines do recommend parental
karyotyping as part of the evaluation in RM couples with
a high risk of carrier status [4,5] but only if maternal age is
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two or more miscarriages in first degree relatives [53].
Some clinicians recommend in vitro fertilization with
preimplantation genetic diagnosis (PGD) as a treatment
option in RM couples with carrier status in order to
replace euploid embryos only. This may be beneficial in
couples with coexisting infertility, but in couples with
proven fertility the live birth rate seems to be comparable
or maybe even higher after spontaneous conception
including PGD [54,55].
Immunological and immunogenetic causes
It has long been an enigma how the implanting embryo
and trophoblast escape maternal immunological rejec-
tion in the uterus in spite of carrying allogeneic proteins
encoded by paternal genes. A series of mechanisms regu-
lating maternal immune recognition and fetal antigen
expression has been suggested to prevent the rejection of
the majority of pregnancies, but these may cause RM
when they fail.
Since reproductive success is of utmost importance for
the survival of a species, it is likely that redundant
mechanisms have developed to prevent immune rejection
of the embryo, and only when several mechanisms fail in a
woman will RM will occur. This complexity continues to
feed the ongoing controversy regarding which immuno-
logical factors play a role in the pathogenesis of RM.
There is general agreement that a series of autoanti-
bodies such as anti-phospholipid, anti-nuclear and anti-
thyroid antibodies can be found with increased prevalence
in RM patients and may display a negative prognostic
impact. However, in humans there is no proof that the
antibodies per se harm the pregnancy; they may simply
be markers of a predisposition to disruption of immuno-
logical self-tolerance and proinflammatory responses in
these women. In contrast, a study found that pregnant
mice injected with human IgG from a patient with
anti-phospholipid antibodies significantly increased
fetal resorption rate and reduced fetal weight while
simultaneous treatment with antibodies blocking activation
of the complement cascade completely prevented fetal
resorptions and growth retardation [6]. In this and similar
studies it was also found that mice deficient in various
complement factors were resistant to fetal injury induced
by injection of the anti-phospholipid antibodies. This in-
dicates that at least in mice, anti-phospholipid antibodies
may exercise their harmful effect on pregnancies through
immunological mechanisms (complement activation)
rather than through a direct procoagulant effect. There is
some, however, weaker evidence that anti-phospholipid
antibodies also induce complement activation in humans
with antiphospholipid syndrome [7].
A series of studies have reported that increased con-
centrations of proinflammatory or T helper cell type Icytokines [56] or increased frequencies of subsets of
natural killer (NK) cells in the blood [8] can be found
during euploid sporadic miscarriage and in women with
RM but it is debated whether measurements of these
biomarkers in peripheral blood reflect conditions at the
fetomaternal interface. There is some evidence that uterine
NK cells regulate angiogenesis in the non-pregnant
endometrium and therefore may also play a role for
implantation and early pregnancy [9] but a systematic
review of relevant studies did not find peripheral blood or
uterine NK cell density or activity to be predictive for
pregnancy outcome in patients with RM [10].
The most convincing evidence for the importance of
the immune system in miscarriage and RM comes
from genetic/epidemiologic studies showing that genetic
biomarkers of possible importance for immunologic dys-
regulation in pregnancy are found with increased fre-
quency in women with RM and display a negative impact
on the prognosis. Examples of such genetic biomarkers
are maternal homozygocity for a 14 base-pair insertion
in the human leukocyte antigen (HLA)-G gene [11],
maternal carriage of HLA class II alleles predisposing to
immunity against male-specific minor histocompatibility
antigens found on male embryos [57], specific maternal
NK cell receptor genotypes in combination with fetal
HLA-C genotypes that may be associated with aberrant
maternal NK cell recognition of the trophoblast [58] and
maternal mannose-binding lectin binding genotypes pre-
disposing to low plasma levels of mannose-binding lectin,
which may be of importance for release of cytokines and
clearance of apoptopic trophoblast cells [59].
Proposed treatment options for RM where immuno-
logic dysregulation is suggested to play a role include
prednisone, allogeneic lymphocyte immunization, intra-
venous immunoglobulin infusion and injection of tumor
necrosis factor α (TNFα) antagonists or granulocyte colony-
stimulating factor (G-CSF). Much controversy exists
about the efficacy of these treatments since the majority
have not been subject to rigorous clinical study or have
only been tested in few and small randomized controlled
trials [60].
The best documented immunological treatment is intra-
venous immunoglobulin (IvIg), which in a recent meta-
analyses in women with secondary RM was shown to
improve the chance of live birth compared with placebo
(OR = 1.89, 95% CI 0.93 to 3.85) [61]. However, this effect
did not reach statistical significance and appropriately
powered randomized controlled trials focusing on this
patient subset are required to elucidate the clinical
value of this therapeutic approach. In mice models
there is good evidence that both unfractionated and
low-molecular-weight heparin prevented complement
activation and protected against pregnancy complica-
tions induced by injection of IgG from patients with
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logical effects of heparin [62].
Thrombophilias
Thrombophilic factors predisposing to thromboembolic
events are associated with both sporadic miscarriages
and RM and can be hereditary or acquired [12]. It is
suggested that the association is caused by an increased
risk of thrombus formation in the nascent placental vessels
resulting in placenta infarctions. Hereditary factors include
deficiency of antithrombin, protein C and protein S or
carriage of the factor V Leiden or factor II (G20210A)
gene mutations. Acquired factors include the presence
of anti-phospholipid antibodies, lupus anticoagulant or
anti-cardiolipin antibodies, which are deemed to be present
when identified in repeated samples taken 3 months apart
and outwith pregnancy. Hyperhomocysteinemia can be
both hereditary and acquired. There is some evidence
from two non-blinded randomized controlled trials that
treatment with low-dose heparin and aspirin during
pregnancy increases the chance of live birth in RM
patients with anti-phospholipid antibodies [14]. There is
no evidence that anticoagulation therapy will improve the
prognosis for RM patients with hereditary thrombophilias
or no thrombophilia factors at all [13], and results from
relevant ongoing randomized controlled trials are awaited
(for example, the ALIFE2 study). Therapy with high-dose
folate will lower plasma homocysteine levels but there is
no evidence from clinical trials whether this decreases the
risk of a new miscarriage.
Endocrinological causes
The prevalence of hypothyroidism with or without under-
lying thyroid autoimmunity is significant among fertile
women in fertile age. There is evidence that thyroid
dysfunction and thyroid autoimmunity is associated
with infertility and pregnancy loss both in the situation
where the woman is euthyroid with thyroid antibodies
and in a thyroid antibody negative woman with an ele-
vated level of thyroid stimulating hormone (TSH) [15].
According to a recent meta-analysis of 38 studies, the
presence of antibodies against thyroperoxidase (TPO-Ab)
increased the risk of sporadic miscarriage with an odds
ratio of 3.73 (95% CI 1.8 to 7.6) as well as RM (OR 2.3, 95%
CI 1.5 to 3.5) [16]. In a large prospective study including
pregnant thyroid antibody negative women, a TSH level
within the normal range but higher than 2.5 mIU/L in the
first trimester, nearly doubled the risk of a miscarriage
[17]. However, the true significance of thyroid dysfunction
and the value of its correction in improving outcomes in
RM remains unclear.
Polycystic ovarian syndrome (PCOS) is a common endo-
crine disorder of reproductive-age women. PCOS may be
associated with ovulatory disorder and miscarriage whenfertility is desired. Using strict criteria the prevalence
of PCOS among women with RM is estimated to be
8.3% to 10% [18]. The mechanisms behind an increased
miscarriage risk in women with PCOS remains partly
unclear. The current view is that the main cause may be
the associated obesity, which is dealt with in the section
describing lifestyle factors.
Sperm DNA fragmentation
Sperm DNA integrity is essential to reproduction, and
measurement of sperm DNA fragmentation (SDF) was
therefore first introduced as an additional tool in
predicting male infertility. Indeed there is a correlation
between low semen quality and high SDF levels, but at
present much controversy exists with regard to cut-off
levels, which assay to use, and the clinical relevance of
the tests in assisted reproductive technologies [63].
In contrast, there is a documented link between DNA
damage in sperm and miscarriage. A recent meta-analysis
including 16 studies found a highly significant increase in
miscarriage rate in couples where the male partner had
elevated levels of sperm DNA damage compared to those
where the male partner had low levels of sperm DNA
damage (risk ratio = 2.16 (1.54, 3.03, P <0.00001) [19].
Due to variation in study characteristics, the authors have
subgrouped the included studies according to whether
raw or prepared semen was analyzed, and according to
which type of assay was used to determine sperm DNA
damage. A consistent and significant association with mis-
carriage was found regardless of which semen preparation
was used while the strongest association as regards assays
was found in a test quantifying sperm DNA damage
directly by incorporating a labeled enzyme into single and
double-stranded DNA breaks.
In a study comparing fertile sperm donors with couples
who have unexplained RM, an assay was used that both
measured DNA damage directly and also distinguished
between single-stranded and double-stranded DNA
damage. The study showed that 85% of the RM couples
had a profile with high values of double-stranded DNA
damage compared to only 33% among fertile sperm donors,
suggesting a specific paternal explanation in these other-
wise unexplained cases [20].
In the future, assays detecting sperm DNA damage may
be introduced into the evaluation of couples who experi-
ence RM, and in an infertility setting the development of
methods that select sperm without DNA damage may be
helpful in reducing the risk of miscarriage.
Failure of embryo selection
Recent in vitro studies of embryo-decidual interactions
have demonstrated that decidualized stromal cells act as
a biosensor for embryonic derived signals and appear
capable of ‘selecting’ embryos for implantation on the
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biosensor function of decidualized endometrial stromal
cells (ESC) showed that coculture with an arresting
human embryo elicited a reduction in the production
of key cytokine regulators of implantation including
interleukin (IL)-1β, heparin-binding epidermal growth
factor-like growth factor (HB-EGF), IL-6, and IL-10
[21]. These findings provided the first experimental
evidence to support the hypothesis initially put forward by
Quenby et al. that some women with RM may be allowing
embryos of poor viability to implant inappropriately [22].
In other words, women who experience RM may not be
rejecting healthy embryos, but rather permitting embryos
of low viability to implant long enough to present as a
clinical pregnancy before rather than being lost as a pre-
clinical biochemical pregnancy.
The hypothesis that endometrial selectivity to embryo
quality may be disrupted in women with RM has found
support from a number of other studies. Women with RM
have been shown to express lower levels of endometrial
mucin 1, an antiadhesion molecule that contributes to
the barrier function of the epithelium [23]. Moreover,
ESCs of women with RM show an abnormal response
to decidualization in vitro, manifest by attenuated pro-
lactin (PRL) production and prolonged and enhanced
prokineticin 1 expression [24]. It has been proposed that
this may result in a prolonged ‘window’ of receptivity to
implantation, but a reduction in the selective functions of
the decidua [25].
If women with RM are less selective to embryos
implanting, then it would be expected that they would
report shorter intervals between pregnancies. This has
indeed been demonstrated in a retrospective cohort study
of 560 RM women, which showed a significantly greater
proportion to have time-to-pregnancy intervals of 3 months
or less compared with fertile control subjects [24].
Further experimental evidence supporting low endomet-
rial selectivity or ‘super receptivity’ in women with RM
has come from studies of stromal cell migration in vitro.
Recently it has been shown that ESC migration occurs
around the time of embryo implantation and may promote
implantation by encapsulation of the conceptus [64,65]. In
timelapse imaging studies covering a period of 48 h, ESC
migration was clearly depicted at the site of embryo
implantation. Moreover, the ESCs showed migration around
the embryo suggesting an active role for ESCs in the
implantation process [64].
Migration (scratch) assays have provided further evi-
dence for altered embryo selectivity in women with RM.
In a recent study, the directed migration of decidualized
ESCs from normal fertile and RM women in the presence
or absence of a high-quality or low-quality (chromosomally
abnormal 3PN) embryo was observed [26]. The migration
of ESCs from normal fertile women was totally inhibited inthe presence of a low-quality embryo. However, the
migration behavior of ESCs from women with RM was
similar in the presence of both low-quality and high-
quality embryos (Figure 2). In addition, in the presence of
AC-1 M88 trophoblast cell-line-derived spheroids, the
migration of ESCs from women with RM was enhanced
compared to the normal fertile ESCs [26]. These observa-
tions suggest that ESCs from women with RM have an
increased migratory potential in response to trophoblast
signals and are more receptive (and thus less selective) for
low-quality embryos than normally fertile women.
The clinical significance of these findings remains to be
clarified, but failure of embryo selection may represent a
single pathological pathway responsible for both euploidic
and aneuploidic pregnancy losses. Brosens and Gellersen
[65] have noted that given the high proportion of chromo-
somally abnormal preimplantation human embryos, this
concept predicts that the likelihood of euploidic pregnancy
failure increases with the number of miscarriages. This
has indeed been shown to be the case [41].
This novel concept requires further elucidation and
confirmation, but a growing body of evidence supports
the notion of an active, selective decidual phenotype,
which if disrupted may result in reproductive failure.
Novel therapeutic options may thus be developed that
can correct defects in selectivity, preventing inappro-
priate implantation of embryos of low viability and
sparing women the severe stress caused by recurrent
clinical miscarriage. Alternatively, in vitro fertilization
and PGD may improve outcomes in this context as
in vitro embryo selection would increase the chance of
a viable embryo implanting. However, the efficacy of
PGD in treating women with recurrent miscarriage due
to translocations is unclear [54,66], and further studies are
required.Uterine malformations
An accepted cause of recurrent pregnancy loss is uter-
ine malformations that may be acquired or congenital.
The latter include didelphic, bicornuate, arcuate, and
septate uteri. In a recent systematic review including
89,861 women, the prevalence of all congenital uterine
malformations was 5.5% (95% CI 3.5 to 8.5) in an unse-
lected population and 15.4% (95% CI 10.3 to 23)
among women with ≥3 miscarriages [27]. In another
review comprising 3,805 women the meta-analysis
showed that a septate uterus increased the rate of a
first trimester miscarriage significantly when compared
with women with normal uteri (RR = 2.89; 95% CI 2.02
to 4.14) [28]. The role of septal resection is being
debated. Non-controlled studies suggest a positive effect
on pregnancy outcome but we still lack prospective
randomized trials [67].
Figure 2 The migration zone after adding a high-quality, low-quality or no embryo. The migratory response of decidualized human
embryonic neural stem cells (H-EnSCs) from normally fertile (A-C) and recurrent miscarriage (RM) women (D-F) was analyzed in absence of a
human embryo (A,D), in presence of a high-quality embryo (B,E) or a low-quality embryo (C,F). Phase contrast pictures were taken 18 h after
creating the migration zone. The dotted line represents the front of the migration zone directly after its creation. As a reference for the position of the
embryo, the bottom of the plate was marked. The arrows indicate the position of the embryo. All pictures were taken with 25 × magnification.
(Reproduced from Weimar et al. [26]).
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hCG is a glycoprotein composed of two subunits, α and
β. Increasing amounts are secreted from the syncytio-
trophoblast with increased gestation in the first trimester
and bind to luteinizing hormone (LH)/hCG receptors on
the corpus luteum preventing it from regression.
It is well known that early miscarriage is normally
associated with low or suboptimally increasing hCG
levels. The association between low hCG production
and miscarriage can be interpreted in two ways: (1) the
trophoblast growth may be delayed due to embryonal
aneuploidy, immune or thrombophilic disturbances and
low hCG production is a secondary phenomenon, or (2)
the fetoplacental unit may secrete inadequate hCG due to
a primary failure of the trophoblast to produce hCG,
which will result in inadequate progesterone production
and resulting embryonal death. Whereas the former
condition in theory would not benefit from external
hCG supplementation the latter condition may be treatable
with external hCG or progesterone.
If the theory that some miscarriages are due to a primary
failure of the trophoblast to produce hCG, the cause could
be genetic. The β subunit of hCG is coded by four closely
linked duplicate chorionic gonadotropin β (CGB) genes
on chromosome 19, with CGB5 and CGB8 being the most
active [68]. There is an association between levels of
mRNA hCG-β transcripts in trophoblast tissue and plasmahCG levels and the levels of hCG-β mRNA seem to
be lower in tissue from RM than from normal first
trimester pregnancies or ectopic pregnancies. Specific
polymorphisms in the promoter region of the CGB5 gene
that may enhance hCG-β transcription have been found
with lower prevalence in RM than in fertile couples [29]
suggesting that some miscarriages in RM couples may be
caused by polymorphism in the CGB genes. Couples with
such polymorphisms may be those who would benefit
from hCG supplementation, but this must be tested in
prospective trials.
Recently, evidence has been presented suggesting that
epigenetic disruptions may lie behind some instances of
early pregnancy loss. During implantation embryos undergo
demethylation and remethylation of DNA, which is crucial
to their further development and health. In a study com-
paring methylation in embryos from medically terminated
pregnancies with those from spontaneous losses, the villi
derived from embryos lost in early pregnancy were found
to express lower levels of DNA methyltransferase 1, an
enzyme involved in maintaining methylation [69]. However,
whether or not this is a causal rather than associated
phenomenon with miscarriage remains to be elucidated.
Numerous candidate genes associated with a small increase
in the risk of early pregnancy loss have so far been
described. The relative risk of miscarriage attributed to
the carriage of most of these genetic polymorphisms is
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of the patients and screening for the polymorphisms is
therefore not clinical useful [30,41,70].
Lifestyle factors
Women experiencing sporadic as well as RM often have
many questions regarding lifestyle factors. Although
pregnant women are advised to refrain from alcohol a
national Danish birth cohort study including nearly
100,000 pregnant women showed that 45% had some
level of alcohol intake [31]. Even small amounts of alcohol
increased the risk of a miscarriage significantly and further,
the results suggested that the risk increased in a dose-
related manner. Thus, the adjusted hazard ratio for a first
trimester miscarriage was 1.66 and 2.82 when having 2 to
3.5 drinks per week and >4 drinks per week, respectively.
In contrast to alcohol consumption, coffee drinking in
pregnancy is fully acceptable in many countries. Another
Danish study has looked into the association between
miscarriage and coffee intake [71]. Only in cases where
mothers were drinking more than seven cups of coffee
a day could the authors demonstrate an increased risk
of miscarriage (adjusted hazard ratio 1.48 (95% CI 1.01
to 2.17)).
Smoking-related complications in late pregnancy are
substantial and well documented. In contrast, data are
sparse and conflicting when it comes to smoking and
miscarriage. As such, a recent review reports an increased
risk of pregnancy loss among smokers [72] whereas a large
prospective study including 24,608 pregnancies could
not demonstrate an association between smoking and
miscarriage [73].
There are many pregnancy-related complications associ-
ated with obesity, including miscarriage. A meta-analysis
from 2008 including primarily studies on infertile popula-
tions showed significantly increased miscarriage rates
when women with a body mass index (BMI) ≥25 kg/m2
were compared to women with a BMI <25 kg/m2 [74].
This tendency has also been demonstrated in women with
RM although it must be emphasized that a significantly
increased risk of another miscarriage was demonstrated
only in obese women; that is, BMI ≥30 kg/m2 [32].
Interestingly, a logistic regression analysis showed that
after advanced maternal age, increased BMI was the most
important risk factor in predicting another miscarriage in
women with RM.
A recent systematic review including 5 retrospective
studies, 1 prospective study and a total cohort of nearly
30,000 women has investigated the relation between
miscarriage rates and obesity (BMI ≥28 or 30 kg/m2)
after spontaneous conception [33]. Indeed, they also
found a significant association both as regards sporadic
and RM implying an urgent need for prospective studies
to assess the value of reducing BMI.Conclusions
Reproductive failure is a common complication in early
pregnancy, with up to two-thirds of all fertilized oocytes
not producing live births. Thus, a large number of concep-
tions either fail to implant or are categorized as biochem-
ical pregnancies and clinical miscarriages. Although, the
incidence of karyotypic abnormalities in the parents is low
this high rate of early losses is most certainly connected to
a high frequency of sporadic karyotypic abnormalities in
the products of conception. In couples experiencing RM,
however, a parental chromosomal anomaly is found ten
times more frequently than in the background population
and whether these couples should be offered PGD or await
prenatal invasive diagnosis once a spontaneous pregnancy
has been established is a matter under debate. Soon, se-
quencing of the entire fetal genome from free fetal DNA in
the maternal circulation will be a standard procedure and
will hopefully have the potential to increase our under-
standing of embryonic causes of both sporadic and RM.
Biomarkers associated with predisposition to throm-
bophilia or autoimmunity can be found with increased
prevalence in women with RM and affect the prognosis
negatively, but it is still unclear to what extent anti-
coagulation and immune modulation therapies can improve
pregnancy outcome in these cases. Recent studies have
highlighted the importance of genetically determined
differences in capacity for hCG production and in markers
of sperm DNA damage.
The emerging role of the endometrium as a biosensor of
embryo quality, which may be less discerning in some
women, also provides a novel mechanism underlying RM
that merits further study. Sporadic miscarriage can be seen
as representing nature’s quality control system, preventing
embryos with severe abnormalities in most cases from
progressing beyond the peri-implantation period. Should
this quality control be disrupted, such embryos may be
allowed to establish implantation long enough to present
as clinical pregnancy before failing, resulting in recurrent
clinical miscarriage. Clearly, if an embryo is of high quality,
then having a less selective endometrium will not have
clinical consequences, and an ongoing pregnancy may
ensue. Consistent with this, most women with RM will
achieve an ongoing pregnancy if they persist in trying.
However, other concurrent medical conditions outlined
in this article may prevent the ready establishment of
ongoing pregnancy. Recent and ongoing research is clarify-
ing the varying mechanisms underlying the very distressing
condition of RM and offer new opportunities for developing
effective interventions.
Abbreviations
BMI: Body mass index; ESC: Endometrial stromal cells; ESHRE: European
Society of Human Reproduction and Embryology; hCG: Human chorionic
gonadotropin; PCOS: Polycystic ovarian syndrome; PGD: preimplantation
genetic diagnosis; RM: Recurrent miscarriage.
Larsen et al. BMC Medicine 2013, 11:154 Page 9 of 10
http://www.biomedcentral.com/1741-7015/11/154Competing interests
The authors declare they have no competing interests.
Authors’ contributions
NM, ECL and OBC made substantial contributions to conception and design.
ECL, OBC, AMK, and NM contributed equally to the literature review,
interpretation and writing of the manuscript. NM and OBC revised the
manuscript critically. All authors read and approved the final manuscript.
Authors’ information
ECL and OBC run the largest recurrent miscarriage clinic in Denmark. OBC is a
senior member of the ESHRE Special Interest Group in Early Pregnancy Loss.
NM has longstanding clinical and research interest in early pregnancy loss. All
authors have published numerous papers and book chapters in this field.
Author details
1The Fertility Clinic, Juliane Marie Centre, Rigshospitalet, University of
Copenhagen, Copenhagen, Denmark. 2Department of Obstetrics and
Gynaecology, Aalborg Hospital, Aalborg, Denmark. 3Division of Human
Development and Health, University of Southampton, Southampton, UK.
4Obstetrics and Gynaecology, Academic Unit of Human Development and
Health, University of Southampton, Southampton, UK. 5Complete Fertility
Centre Southampton, Princess Anne Hospital, Coxford Road, Southampton
SO16 5YA, UK.
Received: 12 March 2013 Accepted: 29 May 2013
Published: 26 June 2013
References
1. Farquharson RG, Jauniaux E, Exalto N: Updated and revised nomenclature for
description of early pregnancy events. Hum Reprod 2005, 20:3008–3011.
2. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N: Evidence-based
guidelines for the investigation and medical treatment of recurrent
miscarriage. Hum Reprod 2006, 21:2216–2222.
3. Silver RM, Branch DW, Goldenberg R, Iams JD, Klebanoff MA: Nomenclature
for pregnancy outcomes: time for a change. Obstet Gynecol 2011,
118:1402–1408.
4. Practice Committee of the American Society for Reproductive Medicine:
Evaluation and treatment of recurrent pregnancy loss: a committee
opinion. Fertil Steril 2012, 98:1103–1111.
5. Royal College of Obstetricians and Gynaecologists SAC: Guideline No. 17. The
investigation and treatment of couples with first and second trimester
recurrent miscarriage. London, UK: Royal College of Obstetricians and
Gynaecologists; 2011:1–18.
6. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola
R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE: Complement C3 activation
is required for antiphospholipid antibody-induced fetal loss. J Exp Med
2002, 195:211–220.
7. Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, Yasuda S,
Koike T: Complement activation in patients with primary
antiphospholipid syndrome. Ann Rheum Dis 2009, 68:1030–1035.
8. King K, Smith S, Chapman M, Sacks G: Detailed analysis of peripheral
blood natural killer (NK) cells in women with recurrent miscarriage. Hum
Reprod 2010, 25:52–58.
9. Quenby S, Nik H, Innes B, Lash G, Turner M, Drury J, Bulmer J: Uterine
natural killer cells and angiogenesis in recurrent reproductive failure.
Hum Reprod 2009, 24:45–54.
10. Tang AW, Alfirevic Z, Quenby S: Natural killer cells and pregnancy
outcomes in women with recurrent miscarriage and infertility: a
systematic review. Hum Reprod 2011, 26:1971–1980.
11. Christiansen OB, Kolte AM, Dahl M, Larsen EC, Steffensen R, Nielsen HS,
Hviid TV: Maternal homozygocity for a 14 base pair insertion in exon 8 of
the HLA-G gene and carriage of HLA class II alleles restricting HY
immunity predispose to unexplained secondary recurrent miscarriage
and low birth weight in children born to these patients. Hum Immunol
2012, 73:699–705.
12. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID,
Greaves M, Brenkel I, Regan L, Greer IA: Thrombophilia in pregnancy: a
systematic review. Br J Haematol 2006, 132:171–196.
13. McNamee K, Dawood F, Farquharson R: Recurrent miscarriage and
thrombophilia: an update. Curr Opin Obstet Gynecol 2012, 24:229–234.14. Lassere M, Empson M: Treatment of antiphospholipid syndrome in
pregnancy - a systematic review of randomized therapeutic trials.
Thromb Res 2004, 114:419–426.
15. Twig G, Shina A, Amital H, Shoenfeld Y: Pathogenesis of infertility and
recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun 2012,
38:J275–J281.
16. van den Boogaard E, Vissenberg R, Land JA, van Wely M, van der Post JA,
Goddijn M, Bisschop PH: Significance of (sub)clinical thyroid dysfunction
and thyroid autoimmunity before conception and in early pregnancy: a
systematic review. Hum Reprod Update 2011, 17:605–619.
17. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A:
Increased pregnancy loss rate in thyroid antibody negative women with
TSH levels between 2.5 and 5.0 in the first trimester of pregnancy.
J Clin Endocrinol Metabol 2010, 95:E44–E48.
18. Cocksedge KA, Saravelos SH, Metwally M, Li TC: How common is polycystic
ovary syndrome in recurrent miscarriage? Reprod Biomed Online 2009,
19:572–576.
19. Robinson L, Gallos ID, Conner SJ, Rajkhowa M, Miller D, Lewis S, Kirkman-
Brown J, Coomarasamy A: The effect of sperm DNA fragmentation on
miscarriage rates: a systematic review and meta-analysis. Hum Reprod
2012, 27:2908–2917.
20. Ribas-Maynou J, Garcia-Peiro A, Fernandez-Encinas A, Amengual MJ, Prada
E, Cortes P, Navarro J, Benet J: Double stranded sperm DNA breaks,
measured by Comet assay, are associated with unexplained recurrent
miscarriage in couples without a female factor. PLoS One 2012, 7:e44679.
21. Teklenburg G, Salker M, Molokhia M, Lavery S, Trew G, Aojanepong T,
Mardon HJ, Lokugamage AU, Rai R, Landles C, Roelen BA, Quenby S, Kuijk
EW, Kavelaars A, Heijnen CJ, Regan L, Brosens JJ, Macklon NS: Natural
selection of human embryos: decidualizing endometrial stromal cells
serve as sensors of embryo quality upon implantation. PLoS One 2010,
5:e10258.
22. Quenby S, Vince G, Farquharson R, Aplin J: Recurrent miscarriage: a defect
in nature’s quality control? Hum Reprod 2002, 17:1959–1963.
23. Aplin JD, Hey NA, Li TC: MUC1 as a cell surface and secretory component
of endometrial epithelium: reduced levels in recurrent miscarriage.
Am J Reprod Immunol 1996, 35:261–266.
24. Salker M, Teklenburg G, Molokhia M, Lavery S, Trew G, Aojanepong T,
Mardon HJ, Lokugamage AU, Rai R, Landles C, Roelen BA, Quenby S, Kuijk
EW, Kavelaars A, Heijnen CJ, Regan L, Macklon NS, Brosens JJ: Natural
selection of human embryos: impaired decidualization of endometrium
disables embryo-maternal interactions and causes recurrent pregnancy
loss. PLoS One 2010, 5:e10287.
25. Teklenburg G, Salker M, Heijnen C, Macklon NS, Brosens JJ: The molecular
basis of recurrent pregnancy loss: impaired natural embryo selection.
Mol Hum Reprod 2010, 16:886–895.
26. Weimar CH, Kavelaars A, Brosens JJ, Gellersen B, de Vreeden-Elbertse JM,
Heijnen CJ, Macklon NS: Endometrial stromal cells of women with
recurrent miscarriage fail to discriminate between high- and low-quality
human embryos. PLoS One 2012, 7:e41424.
27. Chan YY, Jayaprakasan K, Zamora J, Thornton JG, Raine-Fenning N,
Coomarasamy A: The prevalence of congenital uterine anomalies in
unselected and high-risk populations: a systematic review. Hum Reprod
Update 2011, 17:761–771.
28. Chan YY, Jayaprakasan K, Tan A, Thornton JG, Coomarasamy A, Raine-Fenning
NJ: Reproductive outcomes in women with congenital uterine anomalies: a
systematic review. Ultrasound Obstet Gynecol 2011, 38:371–382.
29. Rull KCO, Nagirnaja L, Steffensen R, Margus T, Laan M: A modest, but
significant effect of CGB5 gene promotor polymorphisms in modulating
the risk of recurrent miscarriage. Fertil Steril 2013, 99:1930–1936.
30. Daher S, Mattar R, Gueuvoghlanian-Silva BY, Torloni MR: Genetic
polymorphisms and recurrent spontaneous abortions: an overview of
current knowledge. Am J Reprod Immunol 2012, 67:341–347.
31. Andersen AM, Andersen PK, Olsen J, Gronbaek M, Strandberg-Larsen K:
Moderate alcohol intake during pregnancy and risk of fetal death.
Int J Epidemiol 2012, 41:405–413.
32. Metwally M, Saravelos SH, Ledger WL, Li TC: Body mass index and risk of
miscarriage in women with recurrent miscarriage. Fertil Steril 2010,
94:290–295.
33. Boots C, Stephenson MD: Does obesity increase the risk of miscarriage in
spontaneous conception: a systematic review. Semin Reprod Med 2011,
29:507–513.
Larsen et al. BMC Medicine 2013, 11:154 Page 10 of 10
http://www.biomedcentral.com/1741-7015/11/15434. Zinaman MJ, Clegg ED, Brown CC, O’Connor J, Selevan SG: Estimates of
human fertility and pregnancy loss. Fertil Steril 1996, 65:503–509.
35. Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, Schlatterer JP, Canfield RE,
Armstrong EG, Nisula BC: Incidence of early loss of pregnancy.
N Engl J Med 1988, 319:189–194.
36. Wang X, Chen C, Wang L, Chen D, Guang W, French J: Conception, early
pregnancy loss, and time to clinical pregnancy: a population-based
prospective study. Fertil Steril 2003, 79:577–584.
37. Macklon NS, Geraedts JP, Fauser BC: Conception to ongoing pregnancy: the
‘black box’ of early pregnancy loss. Hum Reprod Update 2002, 8:333–343.
38. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M: Maternal
age and fetal loss: population based register linkage study. BMJ 2000,
320:1708–1712.
39. Ugwumadu A, Manyonda I, Reid F, Hay P: Effect of early oral clindamycin
on late miscarriage and preterm delivery in asymptomatic women with
abnormal vaginal flora and bacterial vaginosis: a randomised controlled
trial. Lancet 2003, 361:983–988.
40. Carp HJA: Epidemiology of recurrent pregnancy loss. In Recurrent
Pregnancy Loss. London, UK: Informa Healthcare; 2007.
41. Christiansen OB, Steffensen R, Nielsen HS, Varming K: Multifactorial etiology
of recurrent miscarriage and its scientific and clinical implications.
Gynecol Obstet Invest 2008, 66:257–267.
42. Philipp T, Philipp K, Reiner A, Beer F, Kalousek DK: Embryoscopic and
cytogenetic analysis of 233 missed abortions: factors involved in the
pathogenesis of developmental defects of early failed pregnancies.
Hum Reprod 2003, 18:1724–1732.
43. Vanneste E, Voet T, Le Caignec C, Ampe M, Konings P, Melotte C, Debrock S,
Amyere M, Vikkula M, Schuit F, Fryns JP, Verbeke G, D’Hooghe T, Moreau Y,
Vermeesch JR: Chromosome instability is common in human cleavage-stage
embryos. Nat Med 2009, 15:577–583.
44. Kurahashi H, Tsutsumi M, Nishiyama S, Kogo H, Inagaki H, Ohye T:
Molecular basis of maternal age-related increase in oocyte aneuploidy.
Congenit Anom 2012, 52:8–15.
45. Morris JK, Wald NJ, Watt HC: Fetal loss in Down syndrome pregnancies.
Prenat Diagn 1999, 19:142–145.
46. Ogasawara M, Aoki K, Okada S, Suzumori K: Embryonic karyotype of
abortuses in relation to the number of previous miscarriages. Fertil Steril
2000, 73:300–304.
47. Chiu RW, Lo YM: Clinical applications of maternal plasma fetal DNA
analysis: translating the fruits of 15 years of research. Clin Chem Lab Med
2013, 1:197–204.
48. Kitzman JO, Snyder MW, Ventura M, Lewis AP, Qiu R, Simmons LE, Gammill
HS, Rubens CE, Santillan DA, Murray JC, Tabor HK, Bamshad MJ, Eichler EE,
Shendure J: Noninvasive whole-genome sequencing of a human fetus.
Sci Transl Med 2012, 4:137–176.
49. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, Rodriguez
MH, Williams J 3rd, Mitchell ME, Adair CD, Lee H, Jacobsson B, Tomlinson
MW, Oepkes D, Hollemon D, Sparks AB, Oliphant A, Song K: Non-Invasive
Chromosomal Evaluation (NICE) Study: results of a multicenter
prospective cohort study for detection of fetal trisomy 21 and trisomy
18. Am J Obstet Gynecol 2012, 207:137.
50. Dan S, Wang W, Ren J, Li Y, Hu H, Xu Z, Lau TK, Xie J, Zhao W, Huang H,
Sun L, Zhang X, Liao S, Qiang R, Cao J, Zhang Q, Zhou Y, Zhu H, Zhong M,
Guo Y, Lin L, Gao Z, Yao H, Zhang H, Zhao L, Jiang F, Chen F, Jiang H, Li S,
Wang J, et al: Clinical application of massively parallel sequencing-based
prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105
pregnancies with mixed risk factors. Prenat Diagn 2012, 32:1225–1232.
51. Branch DW, Gibson M, Silver RM: Clinical practice. Recurrent miscarriage.
N Engl J Med 2010, 363:1740–1747.
52. Franssen MT, Korevaar JC, van der Veen F, Leschot NJ, Bossuyt PM, Goddijn
M: Reproductive outcome after chromosome analysis in couples with
two or more miscarriages: index [corrected]-control study. BMJ 2006,
332:759–763.
53. Franssen MT, Korevaar JC, Leschot NJ, Bossuyt PM, Knegt AC, Gerssen-
Schoorl KB, Wouters CH, Hansson KB, Hochstenbach R, Madan K, van der
Veen F, Goddijn M: Selective chromosome analysis in couples with two
or more miscarriages: case–control study. BMJ 2005, 331:137–141.
54. Franssen MT, Musters AM, van der Veen F, Repping S, Leschot NJ, Bossuyt
PM, Goddijn M, Korevaar JC: Reproductive outcome after PGD in couples
with recurrent miscarriage carrying a structural chromosome
abnormality: a systematic review. Hum Reprod Update 2011, 17:467–475.55. Lalioti MD: Can preimplantation genetic diagnosis overcome recurrent
pregnancy failure? Curr Opin Obstet Gynecol 2008, 20:199–204.
56. Calleja-Agius J, Jauniaux E, Pizzey AR, Muttukrishna S: Investigation of
systemic inflammatory response in first trimester pregnancy failure.
Hum Reprod 2012, 27:349–357.
57. Nielsen HS, Steffensen R, Varming K, Van Halteren AG, Spierings E, Ryder LP,
Goulmy E, Christiansen OB: Association of HY-restricting HLA class II
alleles with pregnancy outcome in patients with recurrent miscarriage
subsequent to a firstborn boy. Hum Mol Genet 2009, 18:1684–1691.
58. Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffett A: Association of
maternal killer-cell immunoglobulin-like receptors and parental HLA-C
genotypes with recurrent miscarriage. Hum Reprod 2008, 23:972–976.
59. Kruse C, Rosgaard A, Steffensen R, Varming K, Jensenius JC, Christiansen OB:
Low serum level of mannan-binding lectin is a determinant for
pregnancy outcome in women with recurrent spontaneous abortion.
Am J Obstet Gynecol 2002, 187:1313–1320.
60. Porter TF, LaCoursiere Y, Scott JR: Immunotherapy for recurrent
miscarriage. Cochrane Database Syst Rev 2006, 2, CD000112.
61. Ata B, Tan SL, Shehata F, Holzer H, Buckett W: A systematic review of
intravenous immunoglobulin for treatment of unexplained recurrent
miscarriage. Fertil Steril 2011, 95:1080–1085.
62. Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid
antibody-induced fetal loss by inhibiting complement activation. Nat
Med 2004, 10:1222–1226.
63. Beshay VE, Bukulmez O: Sperm DNA damage: how relevant is it clinically?
Curr Opin Obstet Gynecol 2012, 24:172–179.
64. Grewal S, Carver JG, Ridley AJ, Mardon HJ: Implantation of the human
embryo requires Rac1-dependent endometrial stromal cell migration.
Proc Natl Acad Sci USA 2008, 105:16189–16194.
65. Brosens JJ, Gellersen B: Something new about early pregnancy: decidual
biosensoring and natural embryo selection. Ultrasound Obstet Gynecol
2010, 36:1–5.
66. Fischer J, Colls P, Escudero T, Munne S: Preimplantation genetic diagnosis
(PGD) improves pregnancy outcome for translocation carriers with a
history of recurrent losses. Fertil Steril 2010, 94:283–289.
67. Kowalik CR, Goddijn M, Emanuel MH, Bongers MY, Spinder T, de Kruif JH,
Mol BW, Heineman MJ: Metroplasty versus expectant management for
women with recurrent miscarriage and a septate uterus. Cochrane
Database Syst Rev 2011, 6, CD008576.
68. Rull K, Laan M: Expression of β-subunit of HCG genes during normal and
failed pregnancy. Hum Reprod 2005, 20:3360–3368.
69. Yin LJ, Zhang Y, Lv PP, He WH, Wu YT, Liu AX, Ding GL, Dong MY, Qu F, Xu
CM, Zhu XM, Huang HF: Insufficient maintenance DNA methylation is
associated with abnormal embryonic development. BMC Med 2012, 10:26.
70. Chin JR, Heuser CC, Eller AG, Branch DW, Nelson LT, Silver RM: Leptin and
leptin receptor polymorphisms and recurrent pregnancy loss. J Perinatol.
In press.
71. Bech BH, Nohr EA, Vaeth M, Henriksen TB, Olsen J: Coffee and fetal death:
a cohort study with prospective data. Am J Epidemiol 2005, 162:983–990.
72. Saravelos SH, Regan L: The importance of preconception counseling and
early pregnancy monitoring. Semin Reprod Med 2011, 29:557–568.
73. Wisborg K, Kesmodel U, Henriksen TB, Hedegaard M, Secher NJ: A
prospective study of maternal smoking and spontaneous abortion.
Acta Obstet Gynecol Scand 2003, 82:936–941.
74. Metwally M, Ong KJ, Ledger WL, Li TC: Does high body mass index increase
the risk of miscarriage after spontaneous and assisted conception? A meta-
analysis of the evidence. Fertil Steril 2008, 90:714–726.
doi:10.1186/1741-7015-11-154
Cite this article as: Larsen et al.: New insights into mechanisms behind
miscarriage. BMC Medicine 2013 11:154.
